Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mundipharma International extends its collaboration with Infinity Pharmaceuticals by committing more than $50m of funds in 2013 for the development of IPI-145, and Infinity's other development candidates.
Subscribe to our email newsletter
IPI-145 by Infinity is a potent, oral inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma, used in the treatment of hematologic cancers and inflammatory conditions.
IPI-145 is currently undergoing two Phase 1 clinical trials by Infinity.
The first double-blind, randomized, placebo-controlled study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of IPI-145 in healthy adult subjects.
The second trial is an open-label, dose-escalation study intended to assess the safety, pharmacokinetics and clinical activity of IPI-145 in patients with advanced hematologic malignancies.